NasdaqCM - Nasdaq Real Time Price USD

Vaccinex, Inc. (VCNX)

7.43 +0.35 (+4.94%)
At close: June 7 at 4:00 PM EDT
7.26 -0.17 (-2.29%)
After hours: June 7 at 7:57 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
124.00
570.00
275.00
900.00
50.00
--
Cost of Revenue
--
--
--
--
2.00
199.00
Gross Profit
--
--
--
900.00
48.00
324.00
Operating Expense
23,097.00
23,455.00
20,181.00
23,390.00
28,379.00
--
Operating Income
-22,973.00
-22,885.00
-19,906.00
-22,490.00
-28,331.00
--
Net Non Operating Interest Income Expense
-29.00
-1.00
-2.00
-809.00
-489.00
--
Other Income Expense
3,816.00
2,635.00
93.00
919.00
-31.00
--
Pretax Income
-19,186.00
-20,251.00
-19,815.00
-22,380.00
-28,851.00
--
Net Income Common Stockholders
-19,186.00
-20,251.00
-19,815.00
-22,380.00
-28,851.00
--
Diluted NI Available to Com Stockholders
-19,186.00
-20,251.00
-19,815.00
-22,380.00
-28,851.00
--
Basic EPS
-25.73
-43.68
-98.05
-163.80
-323.40
--
Diluted EPS
-25.73
-43.68
-98.05
-163.80
-323.40
--
Basic Average Shares
736.08
463.65
202.08
137.38
89.46
--
Diluted Average Shares
736.08
463.65
202.08
137.38
89.46
--
Total Operating Income as Reported
-22,973.00
-22,885.00
-19,906.00
-22,490.00
-28,331.00
--
Total Expenses
23,097.00
23,455.00
20,181.00
23,390.00
28,381.00
--
Net Income from Continuing & Discontinued Operation
-19,186.00
-20,251.00
-19,815.00
-22,380.00
-28,851.00
--
Normalized Income
-22,115.00
-21,974.00
-19,815.00
-23,256.00
-28,851.00
--
Interest Expense
29.00
1.00
2.00
809.00
489.00
--
Net Interest Income
-29.00
-1.00
-2.00
-809.00
-489.00
--
EBIT
-19,157.00
-20,250.00
-19,813.00
-21,571.00
-28,362.00
--
EBITDA
-19,042.00
-20,131.00
-19,606.00
-21,402.00
-28,055.00
--
Reconciled Cost of Revenue
--
--
--
--
2.00
199.00
Reconciled Depreciation
115.00
119.00
207.00
169.00
307.00
--
Net Income from Continuing Operation Net Minority Interest
-19,186.00
-20,251.00
-19,815.00
-22,380.00
-28,851.00
--
Total Unusual Items Excluding Goodwill
2,929.00
1,723.00
--
876.00
--
--
Total Unusual Items
2,929.00
1,723.00
--
876.00
--
--
Normalized EBITDA
-21,971.00
-21,854.00
-19,606.00
-22,278.00
-28,055.00
--
12/31/2019 - 8/9/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DRMA Dermata Therapeutics, Inc.
3.3000
-5.44%
 
ALGS Aligos Therapeutics, Inc.
0.5401
-6.56%
 
CYCC Cyclacel Pharmaceuticals, Inc.
2.0000
+1.01%
 
FBLG FibroBiologics, Inc.
9.59
-6.98%
 
QLGN Qualigen Therapeutics, Inc.
0.2000
-9.09%
 
REPL Replimune Group, Inc.
7.90
+11.11%
 
ACIU AC Immune SA
4.7700
-2.05%
 
MNPR Monopar Therapeutics Inc.
0.8110
-12.70%
 
GNPX Genprex, Inc.
2.4500
-10.42%
 
BCDA BioCardia, Inc.
3.7200
-14.87%